第二线和第三线生物制剂在围克罗恩病中的有效性 - - 一项多中心倾向得分匹配的研究
Uria Shani1, Monica State2, Radu Bogdan Mateescu2
1Department of Internal Medicine B, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Journal of Crohn's & colitis
|June 10, 2025
概括
乌斯特基努马布在对初始治疗没有反应的近克罗恩病患者的治疗中显示出比维多利祖马布或其他抗瘤缩因子-α抑制剂更高的疗效. 这项研究比较了活跃周病的二线和三线生物疗法.
科学领域:
- 胃肠病学和肝病学
- 免疫学 免疫学 免疫学
- 炎症性肠道疾病研究研究
背景情况:
- 抗瘤坏死因子α抑制剂 (抗TNFs) 是围克罗恩病 (pCD) 的标准,但治疗失败频繁.
- 关于二线和三线生物疗法在pCD中的疗效的数据有限.
- 这项研究提供了首次直接比较抗TNF失败后对pCD的先进生物治疗方法.
研究的目的:
- 为了比较第二线和第三线生物疗法的有效性,在患有活跃周克罗恩病 (pCD) 的患者中.
- 评估乌斯特基努马布 (UST),维多利祖马布 (VDZ) 和随后的抗TNFs作为pCD的先进治疗选择.
- 为了确定对抗第一线抗TNF治疗耐药的pCD患者的最佳治疗策略.
主要方法:
- 一项多中心回顾性队列研究,涉及患有pCD的成年患者,其一线抗TNF治疗失败.
- 主要结局:临床围反应. 二次结果:放射性反应和愈合,以及临床缓解.
- 倾向性得分匹配 (PSM) 用于控制患者的基线特征.
主要成果:
- 在二线治疗中,乌斯特基努马布 (79.5%) 与vedolizumab (58.9%) 和其他抗TNFs (48.7%) 相比,显示出显著更高的临床围反应率.
- 在第三线治疗中,乌斯特基努马布 (77.6%) 也显示出优异的临床围反应率,相比于韦多利祖马布 (59.2%) 和其他抗TNFs (55.1%).
- 与vedolizumab相比,ustekinumab治疗与更好的放射性反应率有关.
结论:
- 乌斯特基努马布似乎是一个更有效的二线或三线生物疗法,而不是维多利祖马布或其他抗TNF治疗周围门克罗恩病.
- 这些发现表明ustekinumab对于那些对初始抗TNF治疗没有反应的pCD患者来说是一个有前途的选择.
- 需要进一步的前性研究来证实这些在先进的PCD管理中的比较有效性发现.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Inflammatory Bowel Disease II: Crohn's Disease
402
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
402
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244


